Trial Outcomes & Findings for Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD) (NCT NCT00595231)

NCT ID: NCT00595231

Last Updated: 2019-02-27

Results Overview

The Hamilton Anxiety Scale is a 14-item test measuring the severity of anxiety symptoms. It provides measures of overall anxiety, psychic anxiety (mental agitation and psychological distress), and somatic anxiety (physical complaints related to anxiety). The interviewer then rated the individuals on a 5-point scale for each of the 14 items. Seven of the items specifically address psychic anxiety and the remaining 7 items address somatic anxiety. The total anxiety score ranges from 0 to 56. The 7 psychic anxiety items elicit a psychic anxiety score that ranges from 0 to 28. The remaining 7 items yield a somatic anxiety score that also ranges from 0 to 28. A score of 17 or less indicates mild anxiety severity. A score from 18 to 24 indicates mild to moderate anxiety severity, a score of 25 to 30 indicates a moderate to severe anxiety and lastly a score of 31-56 is very severe. HAM-A total score is the sum of items 1 - 14.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

239 participants

Primary outcome timeframe

8 Weeks

Results posted on

2019-02-27

Participant Flow

A total of 239 subjects were randomized into the trial from 19 of the 20 study sites initiated.

Participant milestones

Participant milestones
Measure
Rufinamide
500 mg 1 week, followed by 1000 mg for 7 weeks
Placebo
0 mg. tablet
Overall Study
STARTED
120
119
Overall Study
COMPLETED
115
114
Overall Study
NOT COMPLETED
5
5

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Rufinamide
n=115 Participants
500 mg for 1 week followed by 1000 mg for 7 weeks
Placebo
n=114 Participants
Placebo, 0 mg tablets
Total
n=229 Participants
Total of all reporting groups
Age, Continuous
38.4 years
STANDARD_DEVIATION 12.47 • n=99 Participants
35.6 years
STANDARD_DEVIATION 11.53 • n=107 Participants
37.0 years
STANDARD_DEVIATION 12.07 • n=206 Participants
Sex: Female, Male
Female
76 Participants
n=99 Participants
81 Participants
n=107 Participants
157 Participants
n=206 Participants
Sex: Female, Male
Male
39 Participants
n=99 Participants
33 Participants
n=107 Participants
72 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
12 Participants
n=99 Participants
19 Participants
n=107 Participants
31 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
103 Participants
n=99 Participants
95 Participants
n=107 Participants
198 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
1 Participants
n=107 Participants
1 Participants
n=206 Participants
Race (NIH/OMB)
Asian
12 Participants
n=99 Participants
8 Participants
n=107 Participants
20 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
1 Participants
n=107 Participants
1 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
14 Participants
n=99 Participants
17 Participants
n=107 Participants
31 Participants
n=206 Participants
Race (NIH/OMB)
White
82 Participants
n=99 Participants
69 Participants
n=107 Participants
151 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
7 Participants
n=99 Participants
18 Participants
n=107 Participants
25 Participants
n=206 Participants
Region of Enrollment
United States
115 participants
n=99 Participants
114 participants
n=107 Participants
229 participants
n=206 Participants

PRIMARY outcome

Timeframe: 8 Weeks

Population: ITT Population: Randomized and received at least one dose of the study drugs.

The Hamilton Anxiety Scale is a 14-item test measuring the severity of anxiety symptoms. It provides measures of overall anxiety, psychic anxiety (mental agitation and psychological distress), and somatic anxiety (physical complaints related to anxiety). The interviewer then rated the individuals on a 5-point scale for each of the 14 items. Seven of the items specifically address psychic anxiety and the remaining 7 items address somatic anxiety. The total anxiety score ranges from 0 to 56. The 7 psychic anxiety items elicit a psychic anxiety score that ranges from 0 to 28. The remaining 7 items yield a somatic anxiety score that also ranges from 0 to 28. A score of 17 or less indicates mild anxiety severity. A score from 18 to 24 indicates mild to moderate anxiety severity, a score of 25 to 30 indicates a moderate to severe anxiety and lastly a score of 31-56 is very severe. HAM-A total score is the sum of items 1 - 14.

Outcome measures

Outcome measures
Measure
Rufinamide
n=115 Participants
500 mg 1 week, followed by 1000 mg for 7 weeks
Placebo
n=114 Participants
Placebo, 0 mg tablets
Change From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score: Summary Statistics - Observed
Screening
25.5 score on a scale
Standard Deviation 3.70
25.6 score on a scale
Standard Deviation 3.77
Change From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score: Summary Statistics - Observed
Week 1
21.9 score on a scale
Standard Deviation 6.04
21.4 score on a scale
Standard Deviation 5.71
Change From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score: Summary Statistics - Observed
Week 2
20.0 score on a scale
Standard Deviation 6.29
19.6 score on a scale
Standard Deviation 5.97
Change From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score: Summary Statistics - Observed
Week 3
18.0 score on a scale
Standard Deviation 7.45
17.8 score on a scale
Standard Deviation 7.02
Change From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score: Summary Statistics - Observed
Baseline
25.5 score on a scale
Standard Deviation 3.77
25.8 score on a scale
Standard Deviation 3.74
Change From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score: Summary Statistics - Observed
Week 6
15.7 score on a scale
Standard Deviation 7.34
16.7 score on a scale
Standard Deviation 7.32
Change From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score: Summary Statistics - Observed
Week 8
15.1 score on a scale
Standard Deviation 7.76
15.1 score on a scale
Standard Deviation 7.19
Change From Baseline in Hamilton Anxiety Scale (HAMA) - Total Score: Summary Statistics - Observed
Last Observation
16.7 score on a scale
Standard Deviation 7.91
16.1 score on a scale
Standard Deviation 7.65

PRIMARY outcome

Timeframe: 8 Weeks

Population: ITT Population: Randomized and received at least one dose of the study drugs.

The Hospital Anxiety and Depression Scale is a self screening questionnaire for depression and anxiety. It consists of 14 questions, seven for anxiety and seven for depression. The 14 statements are relevant to either generalized anxiety (7 statements) or 'depression' (again 7). Each question has 4 possible responses. Responses are scored on a scale from 3 to 0. The maximum score is therefore 21 for depression and 21 for anxiety. A score of 11 or higher indicates the probable presence of the mood disorder with a score of 8 to 10 being just suggestive of the presence of the respective state. The 2 subscales, anxiety and depression, have been found to be independent measures. In its current form the HADS is now divided into 4 ranges: normal (0-7), mild (8-10), moderate (11-15) and severe (16-21). Anxiety score = sum of items 1, 3, 5, 7, 9, 11, and 13. Depression score = sum of items 2, 4, 6, 8, 10, 12, and 14.

Outcome measures

Outcome measures
Measure
Rufinamide
n=115 Participants
500 mg 1 week, followed by 1000 mg for 7 weeks
Placebo
n=114 Participants
Placebo, 0 mg tablets
Change From Baseline in Hospital Anxiety and Depression Scale (HADS). Summary Statistics
Week 1
-0.2 score on a scale
Standard Deviation 2.66
-0.1 score on a scale
Standard Deviation 2.02
Change From Baseline in Hospital Anxiety and Depression Scale (HADS). Summary Statistics
Week 6
-1.4 score on a scale
Standard Deviation 3.57
-1.2 score on a scale
Standard Deviation 3.20
Change From Baseline in Hospital Anxiety and Depression Scale (HADS). Summary Statistics
Week 8
-2.0 score on a scale
Standard Deviation 3.61
-1.6 score on a scale
Standard Deviation 3.07
Change From Baseline in Hospital Anxiety and Depression Scale (HADS). Summary Statistics
Last Observation
-1.2 score on a scale
Standard Deviation 3.74
-1.4 score on a scale
Standard Deviation 3.01
Change From Baseline in Hospital Anxiety and Depression Scale (HADS). Summary Statistics
Week 2
-0.4 score on a scale
Standard Deviation 2.42
-0.4 score on a scale
Standard Deviation 2.69
Change From Baseline in Hospital Anxiety and Depression Scale (HADS). Summary Statistics
Week 3
-1.0 score on a scale
Standard Deviation 3.14
-0.5 score on a scale
Standard Deviation 2.91

PRIMARY outcome

Timeframe: 8 Weeks

Population: ITT Population: Randomized and received at least one dose of the study drugs.

The MADRS (Montgomery and Asberg 1979) is a clinician-rated instrument that measures the presence and severity of depression. This instrument consists of 10 items. Each item is rated on a defined step scale of 0 to 6 with anchors at 2-point intervals. The MADRS total score is the sum of the 10 items and ranges from 0 to 60. A high numeric rating shows a greater degree of symptom severity.

Outcome measures

Outcome measures
Measure
Rufinamide
n=115 Participants
500 mg 1 week, followed by 1000 mg for 7 weeks
Placebo
n=114 Participants
Placebo, 0 mg tablets
Change From Baseline in Montgomery-Asberg Depression Scale (MADRS) Summary Statistics.
15.7 score on a scale
Standard Deviation 5.51
16.4 score on a scale
Standard Deviation 4.86

PRIMARY outcome

Timeframe: 8 weeks

Population: ITT Population: Randomized and received at least one dose of the study drugs.

Severity of illness is the first scale in the CGI. A rating is filled in by the investigator at the start of treatment based on a 0-7 point weighted scale. It goes from not assessed (0), to among the most extremely ill patients (7).

Outcome measures

Outcome measures
Measure
Rufinamide
n=115 Participants
500 mg 1 week, followed by 1000 mg for 7 weeks
Placebo
n=114 Participants
Placebo, 0 mg tablets
Change From Baseline in Clinical Global Impression Scale for Severity of Illness: (CGI-S)
4.5 score on a scale
Standard Deviation 0.60
4.4 score on a scale
Standard Deviation 0.56

PRIMARY outcome

Timeframe: 8 weeks

Population: ITT Population: Randomized and received at least one dose of the study drugs.

It explores the extent to which an individual demonstrates depression on three sub-scales (rated 1-5): verbal self-report, behavior and secondary symptoms of depression. Scores range from 3-15, with higher scores indicating greater severity.

Outcome measures

Outcome measures
Measure
Rufinamide
n=115 Participants
500 mg 1 week, followed by 1000 mg for 7 weeks
Placebo
n=114 Participants
Placebo, 0 mg tablets
Change From Baseline Raskin Depression Scale.
5.2 score on a scale
Standard Deviation 1.22
5.3 score on a scale
Standard Deviation 1.20

PRIMARY outcome

Timeframe: 8 weeks

Population: ITT Population: Randomized and received at least one dose of the study drugs.

The Covi Anxiety Scale is a simple 3 item scale for the assessment of severity of anxiety symptoms. The scale measures 3 dimensions: verbal report, behavior and somatic symptoms of anxiety. Each item scored on a scale of 1 - 5. (1)not at all, (2)somewhat, (3)moderately, (4) considerably, and (5)very much), hence the scale is a 5- to 15 point range. The three items are the patient's verbal report (feeling shaky, jittery, jumpy), observed behavior consistent with anxiety during the interview (e.g. appearing frightened, shaky, restless) and somatic complains (e.g., sweating, trembling, heart pounding). COVI Rating Scale total score is the sum of items 1 - 3.

Outcome measures

Outcome measures
Measure
Rufinamide
n=115 Participants
500 mg 1 week, followed by 1000 mg for 7 weeks
Placebo
n=114 Participants
Placebo, 0 mg tablets
Change From Baseline in Covi Anxiety Scale (CAS) - Index Total Score: Summary Statistics Observed
Baseline
10.7 score on a scale
Standard Deviation 1.35
10.6 score on a scale
Standard Deviation 1.33
Change From Baseline in Covi Anxiety Scale (CAS) - Index Total Score: Summary Statistics Observed
Week 3
8.3 score on a scale
Standard Deviation 2.51
8.1 score on a scale
Standard Deviation 1.99
Change From Baseline in Covi Anxiety Scale (CAS) - Index Total Score: Summary Statistics Observed
Screening
10.7 score on a scale
Standard Deviation 1.39
10.5 score on a scale
Standard Deviation 1.26
Change From Baseline in Covi Anxiety Scale (CAS) - Index Total Score: Summary Statistics Observed
Week 6
7.5 score on a scale
Standard Deviation 2.51
7.6 score on a scale
Standard Deviation 2.21
Change From Baseline in Covi Anxiety Scale (CAS) - Index Total Score: Summary Statistics Observed
Week 8
7.1 score on a scale
Standard Deviation 2.50
7.4 score on a scale
Standard Deviation 2.17
Change From Baseline in Covi Anxiety Scale (CAS) - Index Total Score: Summary Statistics Observed
Last Observation
7.7 score on a scale
Standard Deviation 2.73
7.7 score on a scale
Standard Deviation 2.29

Adverse Events

Rufinamide

Serious events: 1 serious events
Other events: 75 other events
Deaths: 0 deaths

Placebo

Serious events: 1 serious events
Other events: 72 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Rufinamide
n=115 participants at risk
500 mg for 1 week followed by 1000 mg for 7 weeks
Placebo
n=114 participants at risk
0 mg tablet
Infections and infestations
Acute Bronchitis
0.87%
1/115 • Number of events 1 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
0.00%
0/114 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
Pregnancy, puerperium and perinatal conditions
Ecotopic Pregnancy
0.00%
0/115 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
0.88%
1/114 • Number of events 1 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.

Other adverse events

Other adverse events
Measure
Rufinamide
n=115 participants at risk
500 mg for 1 week followed by 1000 mg for 7 weeks
Placebo
n=114 participants at risk
0 mg tablet
Eye disorders
Vision Blurred
2.6%
3/115 • Number of events 3 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
0.00%
0/114 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
Gastrointestinal disorders
Abdominal pain
1.7%
2/115 • Number of events 2 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
1.8%
2/114 • Number of events 2 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
Gastrointestinal disorders
Constipation
7.0%
8/115 • Number of events 8 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
0.88%
1/114 • Number of events 1 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
Gastrointestinal disorders
Diarrhoea
2.6%
3/115 • Number of events 5 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
3.5%
4/114 • Number of events 4 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
Gastrointestinal disorders
Dry Mouth
5.2%
6/115 • Number of events 8 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
4.4%
5/114 • Number of events 5 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
Gastrointestinal disorders
Dyspepsia
2.6%
3/115 • Number of events 3 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
1.8%
2/114 • Number of events 2 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
Gastrointestinal disorders
Nausea
8.7%
10/115 • Number of events 12 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
10.5%
12/114 • Number of events 13 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
Gastrointestinal disorders
Vomiting
2.6%
3/115 • Number of events 3 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
2.6%
3/114 • Number of events 4 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
General disorders
Fatigue
3.5%
4/115 • Number of events 4 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
4.4%
5/114 • Number of events 5 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
Infections and infestations
Upper respiratory tract infection
6.1%
7/115 • Number of events 7 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
7.9%
9/114 • Number of events 11 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
Infections and infestations
Urinary tract infection
1.7%
2/115 • Number of events 2 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
2.6%
3/114 • Number of events 3 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
Injury, poisoning and procedural complications
Joint sprain
0.00%
0/115 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
2.6%
3/114 • Number of events 3 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
Metabolism and nutrition disorders
Decreased Appetite
1.7%
2/115 • Number of events 2 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
1.8%
2/114 • Number of events 2 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
Metabolism and nutrition disorders
Increased appetite
1.7%
2/115 • Number of events 2 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
2.6%
3/114 • Number of events 3 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
Musculoskeletal and connective tissue disorders
Athralgia
1.7%
2/115 • Number of events 2 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
1.8%
2/114 • Number of events 3 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
Nervous system disorders
Dizziness
5.2%
6/115 • Number of events 7 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
6.1%
7/114 • Number of events 8 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
Nervous system disorders
Headache
12.2%
14/115 • Number of events 16 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
19.3%
22/114 • Number of events 24 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
Nervous system disorders
Sedation
2.6%
3/115 • Number of events 3 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
0.88%
1/114 • Number of events 2 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
Nervous system disorders
Somnolence
10.4%
12/115 • Number of events 12 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
8.8%
10/114 • Number of events 10 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
Psychiatric disorders
Anxiety
3.5%
4/115 • Number of events 4 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
3.5%
4/114 • Number of events 4 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
Psychiatric disorders
Insomnia
3.5%
4/115 • Number of events 4 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
3.5%
4/114 • Number of events 5 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
Respiratory, thoracic and mediastinal disorders
Sinus congestion
1.7%
2/115 • Number of events 2 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
1.8%
2/114 • Number of events 2 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
Skin and subcutaneous tissue disorders
Dermatitis contact
2.6%
3/115 • Number of events 3 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
0.00%
0/114 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
Skin and subcutaneous tissue disorders
Rash
4.3%
5/115 • Number of events 5 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.
0.00%
0/114 • 8 Weeks
Based on the Safety/Intent-to-Treat (ITT) population. This was defined as all randomized patients who received at least one dose of study medication.

Additional Information

Christopher Kenney, Senior Vice President - Medical Affairs

Acorda Therapeutics

Phone: 9143265775

Results disclosure agreements

  • Principal investigator is a sponsor employee The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding the study results for a period up to 30 days from the date the communication is submitted to the sponsor. The sponsor shall have the right to defer proposed publication an additional 60 days from the end of the review period. The sponsor cannot require changes to the communication and cannot unilaterally extend the embargo.
  • Publication restrictions are in place

Restriction type: OTHER